Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) shares fell 7.2% during trading on Tuesday . The stock traded as low as $25.56 and last traded at $25.3550. 26,588 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 267,385 shares. The stock had previously closed at $27.33.

Analyst Ratings Changes

Several research firms recently commented on ANRO. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Robert W. Baird dropped their price objective on shares of Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Finally, Wedbush dropped their price objective on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, April 2nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Price Performance

The stock has a market capitalization of $813.80 million, a PE ratio of -11.67 and a beta of 2.01. The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock’s 50 day moving average price is $21.19 and its 200-day moving average price is $16.53.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, equities analysts forecast that Alto Neuroscience, Inc. will post -2.48 EPS for the current year.

Institutional Trading of Alto Neuroscience

Large investors have recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares during the period. Barclays PLC lifted its stake in Alto Neuroscience by 72,261.9% in the fourth quarter. Barclays PLC now owns 30,392 shares of the company’s stock worth $541,000 after acquiring an additional 30,350 shares during the period. Alps Advisors Inc. purchased a new stake in Alto Neuroscience in the fourth quarter worth about $454,000. ExodusPoint Capital Management LP purchased a new stake in Alto Neuroscience in the fourth quarter worth about $334,000. Finally, Bridgeway Capital Management LLC lifted its stake in Alto Neuroscience by 43.5% in the third quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock worth $312,000 after acquiring an additional 23,553 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.